Estrella Immunopharma, Inc.
ESLAW· Nasdaq
Released Aug 11, 2025, after the close
10-Q filed Aug 12, 2025, 43 days after period end · 0001213900-25-074567
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$5.54M | -$3.95M | -$76.00K | -$359.59K |
| EPS Diluted | -$0.15 | -$0.11 | — | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Estrella Immunopharma, Inc. · CIK 1844417 · Engraved from SEC EDGAR
20.0% from the close of Aug 7, 2025 to the close of Aug 15, 2025, the first after the release.